DJIA 17,098.45 18.88 0.11%
NASDAQ 4,580.27 22.58 0.50%
S&P 500 2,003.37 6.63 0.33%
market minute promo

Emergent BioSolutions (NYSE: EBS)

24.90 0.03 (0.12%)

REAL-TIME: Last trade at

Extended Hours: $24.90 $0.00 (0.00%)
Quote as of (NYSE)



company name or ticker

Recent Quotes

EBS $24.90 0.12%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $25.00
Previous Close $24.87
Daily Range $24.63 - $25.41
52-Week Range $17.16 - $28.48
Market Cap $933.2M
P/E Ratio 67.22
Dividend (Yield) $0.00 (0.0%)
Volume 161,417
Average Daily Volume 203,134
Current FY EPS $0.66

Sector

Healthcare

Industry

Drugs

Emergent BioSolutions (EBS) Description

Emergent BioSolutions makes the only FDA-approved anthrax vaccine. Website: http://www.emergentbiosolutions.com/

News & Commentary

You Shouldn't Ignore Gilead's Idelalisib

Gilead Sciences is widely known for its HIV drug portfolio and for its high-profile hep-C drug sofosbuvir. But it also has a potential winner with idelalisib, a blood cancer drug with a promising future.

Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog

MorphoSys And Emergent BioSolutions Sign License Agreement to Co-Develop And Commercialize Prostate

MorphoSys And Emergent BioSolutions Sign License Agreement to Co-Develop And Commercialize Prostate Cancer Drug Candidate ES414

Emergent BioSolutions, Inc. (EBS): New Analyst Report from Zacks Equity Research - Zacks Equity Rese

Emergent BioSolutions, Inc. (EBS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Emergent BioSolutions Misses on Earnings, Ups Revenue View - Analyst Blog

Emergent BioSolutions' (EBS) CEO Dan Abdun-Nabi on Q2 2014 Results - Earnings Call Transcript

Emergent BioSolutions (EBS) Q2 2014 Results - Earnings Call Webcast

Will Emergent BioSolutions (EBS) Earnings Disappoint in Q2? - Analyst Blog

Biodel Q2 Loss Wider Than Expected - Analyst Blog

Emergent BioSolutions Enters Oversold Territory (EBS)

Healthcare Stocks Adding to Day-Long Surge; Emergent BioSolutions Slumps After Street.com Downgrade

See More EBS News...

EBS's Top Competitors

EBS $24.90 (0.12%)
Current stock: EBS
AMGN $139.38 (0.50%)
Current stock: AMGN
GILD $107.56 (0.05%)
Current stock: GILD
BIIB $343.04 (0.53%)
Current stock: BIIB